secwatch.observer — SEC 8-K summary
======================================

Issuer:     XWELL, Inc. (XWEL)
CIK:        0001410428
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001104659-25-051002
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XWELL Q1 revenue falls to $7.0M; net loss $4.7M; CDC contract extended 3 years
------------------------------------------------------------------------------

- Revenue $7.0M, down 19% from $8.7M YoY; net loss attributable $4.7M vs $2.5M.
- Cost of sales down 6% to $5.7M; operating expenses down 11% to $4.5M; operating loss $3.2M.
- Closed $4M private placement (Series G preferred + warrants) in Jan 2025; cash $3.7M, marketable securities $7.3M, no debt.
- Secured 3-year extension of CDC Traveler-based Genomic Surveillance Program (TGS) in March 2025.
- Plans to acquire medical spas in Orlando, Dallas, Salt Lake City; new XWELL location at NYC Penn Station mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410428/000110465925051002/0001104659-25-051002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410428/000110465925051002/tm2515209d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-051002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer